NEW YORK (Reuters Health) – Chronic immune-related adverse events (irAEs) associated with anti-programmed cell death-1 (PD-1) therapy for melanoma were more common than previously thought
Read more
Home ยป
(Reuters) – Europe’s drug regulator said on Friday South Korean drugmaker Celltrion’s COVID-19 treatment can be considered for patients at high risk of severe illness,
Read more
NEW YORK (Reuters Health) – The incidence of scleritis has fallen by about a third in the United Kingdom over roughly the past two decades,
Read more
NEW YORK (Reuters Health) – Long-term glucocorticoid (GC) users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab versus oral
Read more
DUBLIN (Reuters) – Ireland is beginning to see strong early evidence that its COVID-19 vaccine rollout is protecting healthcare workers and care home residents from
Read more
NEW YORK (Reuters Health) – Following steroid withdrawal, the anti-CD20 monoclonal antibody rituximab is effective in maintaining long-term remission of steroid-dependent nephrotic syndrome (SDNS) while
Read more